Health ❯ Pharmaceuticals ❯ Weight Loss

Obesity Treatment

Prescription Drugs Semaglutide GLP-1 Hormone

Pfizer Licenses Early-Stage Oral GLP-1 From YaoPharma in Up to $2 Billion Deal

The deal brings an oral obesity candidate into Pfizer’s pipeline, with YaoPharma finishing Phase 1 in Australia before a planned handoff.